Laboratory Corporation of America Holdings (LH) : Traders are bullish on Laboratory Corporation of America Holdings (LH) as it has outperformed the S&P 500 by a wide margin of 1.51% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.43%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.86% in the last 1 week, and is up 4.04% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Laboratory Corporation of America Holdings (NYSE:LH): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $140.49 and $140.20 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $141.32. The buying momentum continued till the end and the stock did not give up its gains. It closed at $140.76, notching a gain of 0.48% for the day. The total traded volume was 774,641 . The stock had closed at $140.09 on the previous day.
The stock has recorded a 20-day Moving Average of 2.21% and the 50-Day Moving Average is 6.27%. Laboratory Corp. of America Holdings is up 13.25% in the last 3-month period. Year-to-Date the stock performance stands at 13.85%.
Laboratory Corporation of America Holdings (LH) : The highest level Laboratory Corporation of America Holdings (LH) is projected to reach is $160 for the short term and the lowest estimate is at $130. The consolidated price target from 14 rating analysts who initiate coverage on the stock is $146.32 and the possibility the share price can swing is $10.1.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.